BMY Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 23.56%. Bristol-Myers Squibb's return on equity of -46.27% beat Gilead Sciences's return on equity of 2.5%.

Bristol-Myers Squibb has a consensus price target of $60.62, signalling upside risk potential of 12.81%. On the other hand Gilead Sciences has an analysts' consensus of $111.67 which suggests that it could grow by 6.1%. Given that Bristol-Myers Squibb has higher upside potential than Gilead Sciences, analysts believe Bristol-Myers Squibb is more attractive than Gilead Sciences.

Bristol-Myers Squibb has a beta of 0.408, which suggesting that the stock is 59.151% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.54%. Gilead Sciences offers a yield of 2.95% to investors and pays a quarterly dividend of $0.79 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are larger than Gilead Sciences quarterly revenues of $7.6B. Bristol-Myers Squibb's net income of $72M is lower than Gilead Sciences's net income of $1.8B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 284.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.26x versus 4.60x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 15.24%. Bristol-Myers Squibb's return on equity of -46.27% beat Johnson & Johnson's return on equity of 19.98%.

Bristol-Myers Squibb has a consensus price target of $60.62, signalling upside risk potential of 12.81%. On the other hand Johnson & Johnson has an analysts' consensus of $171.16 which suggests that it could grow by 13.37%. Given that Johnson & Johnson has higher upside potential than Bristol-Myers Squibb, analysts believe Johnson & Johnson is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.408, which suggesting that the stock is 59.151% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.54%. Johnson & Johnson offers a yield of 3.29% to investors and pays a quarterly dividend of $1.24 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Bristol-Myers Squibb's net income of $72M is lower than Johnson & Johnson's net income of $3.4B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 26.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.26x versus 4.13x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 32.59%. Bristol-Myers Squibb's return on equity of -46.27% beat Eli Lilly and's return on equity of 80.24%.

Bristol-Myers Squibb has a consensus price target of $60.62, signalling upside risk potential of 12.81%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.63 which suggests that it could grow by 34.09%. Given that Eli Lilly and has higher upside potential than Bristol-Myers Squibb, analysts believe Eli Lilly and is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.408, which suggesting that the stock is 59.151% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.54%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Bristol-Myers Squibb's net income of $72M is lower than Eli Lilly and's net income of $4.4B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 64.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.26x versus 15.13x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 23.96%. Bristol-Myers Squibb's return on equity of -46.27% beat Merck &'s return on equity of 40.25%.

Bristol-Myers Squibb has a consensus price target of $60.62, signalling upside risk potential of 12.81%. On the other hand Merck & has an analysts' consensus of $110.89 which suggests that it could grow by 35.37%. Given that Merck & has higher upside potential than Bristol-Myers Squibb, analysts believe Merck & is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.408, which suggesting that the stock is 59.151% less volatile than S&P 500. In comparison Merck & has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.879%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.54%. Merck & offers a yield of 3.86% to investors and pays a quarterly dividend of $0.81 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are smaller than Merck & quarterly revenues of $15.6B. Bristol-Myers Squibb's net income of $72M is lower than Merck &'s net income of $3.7B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Merck &'s PE ratio is 12.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.26x versus 3.24x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.